Dimensional Fund Advisors LP Boosts Holdings in Moderna, Inc. (NASDAQ:MRNA)

Dimensional Fund Advisors LP boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 2.1% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 1,427,300 shares of the company’s stock after purchasing an additional 29,566 shares during the period. Dimensional Fund Advisors LP owned approximately 0.37% of Moderna worth $169,542,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Ashton Thomas Private Wealth LLC acquired a new position in shares of Moderna in the 2nd quarter valued at $26,000. Cedar Wealth Management LLC raised its position in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the period. Westside Investment Management Inc. purchased a new stake in shares of Moderna during the 1st quarter worth about $32,000. Family Firm Inc. acquired a new stake in shares of Moderna during the 2nd quarter valued at about $33,000. Finally, Rise Advisors LLC increased its stake in shares of Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after purchasing an additional 286 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the completion of the sale, the director now owns 2,284,015 shares in the company, valued at approximately $290,572,388.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the completion of the sale, the director now directly owns 2,284,015 shares of the company’s stock, valued at approximately $290,572,388.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The disclosure for this sale can be found here. Insiders have sold 93,158 shares of company stock worth $11,167,312 in the last ninety days. 15.70% of the stock is owned by insiders.

Moderna Stock Performance

NASDAQ MRNA opened at $65.69 on Friday. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The firm has a market capitalization of $25.18 billion, a P/E ratio of -4.19 and a beta of 1.68. The stock’s fifty day moving average is $90.07 and its two-hundred day moving average is $110.76. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. During the same quarter in the prior year, the firm posted ($3.62) earnings per share. Moderna’s quarterly revenue was down 29.9% on a year-over-year basis. On average, research analysts anticipate that Moderna, Inc. will post -9.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MRNA. Oppenheimer downgraded Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday, September 13th. The Goldman Sachs Group decreased their target price on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Piper Sandler cut their price target on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, September 13th. HSBC raised shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective on the stock in a report on Wednesday, August 28th. Finally, TD Cowen cut their target price on shares of Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research note on Friday, September 13th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $100.44.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.